Articles, guides, and regulatory updates from our community.
The GLP-1 revolution has rewritten the rules of obesity treatment. How incretin-based peptide therapies achieve what diet and exercise alone cannot — and what comes next.
By Peptide Association Editorial Team
A head-to-head comparison of the two leading GLP-1 receptor agonists — mechanisms of action, clinical trial data, side effects, and practical considerations for providers and patients.
By Peptide Association Editorial Team